Dr.ย Jong-Seokย Lee
MD, PhD
Professor, Hematology & Medical Oncology
corporate_fareSeoul National University Bundang Hospital, Seongnam
Jong-Seok Lee
MD, PhD
Prof. Jong-Seok Lee is a Full Professor of Hematology and Medical Oncology at Seoul National University Bundang Hospital (SNUBH), one of South Korea's leading academic cancer centres. He holds an MD and PhD from Seoul National University and has been an internationally cited lung cancer specialist for over three decades.
Prof. Lee's clinical and research focus centres on advanced non-small cell lung cancer (NSCLC), with particular expertise in EGFR-mutated disease, ALK-rearranged NSCLC, immunotherapy, and thoracic malignancies including oesophageal cancer and lymphoma. He has contributed to landmark Korean and international clinical trials โ including the Korean subgroup analysis of osimertinib for T790M-positive NSCLC โ and has accumulated more than 29,000 academic citations across over 280 peer-reviewed publications. His long career spans academic posts at Gyeongsang National University followed by senior positions at SNUBH since 2003, giving him one of the most extensive thoracic oncology experience profiles in South Korea.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Lee at Seoul National University Bundang Hospital.
Why Consider Prof. Jong-Seok Lee?
Prof. Lee is one of South Korea's most cited thoracic oncologists, combining deep EGFR and ALK-targeted therapy expertise with active clinical trial participation at a world-class academic medical centre.
Areas of Specialisation
Advanced lung cancer, targeted therapy, immunotherapy and thoracic malignancies
Prof. Lee's specialisation spans the full spectrum of thoracic oncology โ from EGFR and ALK-driven lung cancer to immunotherapy-based approaches, oesophageal cancer, lymphoma, and thymic malignancies.
EGFR-Mutated & ALK-Positive NSCLC
Targeted treatment for driver-mutation-positive non-small cell lung cancer, including third-generation EGFR TKI strategies.
- arrow_rightFirst- and second-generation EGFR TKIs for sensitising mutations
- arrow_rightThird-generation TKIs such as osimertinib for T790M-positive NSCLC
- arrow_rightBiomarker-based patient selection and resistance monitoring
- arrow_rightALK inhibitor therapy for EML4-ALK rearrangement-positive disease
- arrow_rightSequential treatment planning following ALK inhibitor resistance
Immunotherapy for Thoracic Cancers
Checkpoint inhibitor-based treatment and biomarker evaluation for advanced lung and thoracic malignancies.
- arrow_rightPD-1 and PD-L1 inhibitor treatment for eligible NSCLC patients
- arrow_rightCombination immunotherapy and chemotherapy regimens
- arrow_rightBiomarker-guided patient selection including TMB and PD-L1 expression
- arrow_rightSystemic treatment for small cell lung cancer and mesothelioma
- arrow_rightThymic tumour management including thymoma and thymic carcinoma
Lymphoma & Haematologic Oncology
Medical oncology management for haematologic malignancies treated within SNUBH's Division of Hematology-Oncology.
- arrow_rightDiffuse large B-cell lymphoma and other non-Hodgkin lymphomas
- arrow_rightSystemic immunochemotherapy protocols
Procedures Performed
Systemic cancer treatment, targeted therapy and clinical trial participation
Prof. Lee's clinical practice covers a broad range of medical oncology services for thoracic and haematologic cancers, with a strong emphasis on biomarker-driven treatment selection and access to clinical trials at SNUBH.
Targeted Therapy for Driver-Mutation NSCLC
Targeted TherapyPrecision treatment using EGFR and ALK tyrosine kinase inhibitors guided by molecular pathology results.
Immunotherapy & Chemo-Immunotherapy
Medical OncologyCheckpoint inhibitor-based treatment, alone or combined with chemotherapy, for eligible lung cancer patients.
Clinical Trial Participation
MultidisciplinaryAccess to investigational therapies through SNUBH's academic clinical trial programme.
Second Opinion & Case Review
Second OpinionSpecialist review of complex thoracic oncology cases for patients seeking an expert opinion at SNUBH.
Research & Publications
International lung cancer research and peer-reviewed contributions
Prof. Lee has authored or co-authored more than 282 peer-reviewed publications with over 29,000 academic citations, contributing to landmark clinical trials and translational studies in lung cancer, immunotherapy, and thoracic oncology.
A comprehensive publication list for Prof. Lee is available on ResearchGate and PubMed. CancerFax can assist in preparing cases for submission to his team at SNUBH.
Education & Training
Prof. Lee completed his medical and doctoral training at Seoul National University and subsequently trained at leading institutions in South Korea and the United States.
Clinical Experience
Prof. Lee has accumulated over three decades of academic and clinical experience in medical oncology, beginning at Gyeongsang National University and subsequently building a distinguished career at Seoul National University Bundang Hospital from 2003.
Languages & International
Prof. Lee consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients seeking consultation with Prof. Lee.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Jong-Seok Lee
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Jong-Seok Lee's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Jong-Seok Lee's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Jong-Seok Lee before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Jong-Seok Lee's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Jong-Seok Lee's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Jong-Seok Lee's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Jong-Seok Lee
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Lee at Seoul National University Bundang Hospital, subject to hospital availability and case acceptance.
Prof. Lee's primary focus is advanced non-small cell lung cancer, including EGFR-mutated and ALK-positive subtypes. He also treats small cell lung cancer, oesophageal cancer, thymic tumours, mesothelioma, and lymphoma within SNUBH's Division of Hematology-Oncology.
Submit your medical reports through CancerFax. The CancerFax team will review the documents, prepare the case for submission, and coordinate the next steps with Seoul National University Bundang Hospital, subject to availability and case suitability.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, molecular profiling results, imaging, treatment history, and relevant test results. The consultation format and availability depend on Prof. Lee's schedule at SNUBH.
Prof. Lee has extensive expertise in EGFR tyrosine kinase inhibitor (TKI) therapy, including third-generation agents such as osimertinib for patients with T790M-positive acquired resistance. Treatment decisions are guided by comprehensive molecular profiling. He contributed to the Korean subgroup analysis of osimertinib in T790M-positive NSCLC, published in Cancer Research and Treatment in 2020.
Yes. Prof. Lee has a long record of participation in Korean Cancer Study Group (KCSG) multi-centre trials and international industry-sponsored studies in lung cancer and other thoracic malignancies. Eligibility for trial enrolment depends on individual patient criteria and current trial availability at SNUBH.
Connect with Jong-Seok Lee Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.